Tilray (NASDAQ:TLRY) welcomed five individuals to its leadership team to support the company’s aggressive European and international expansion strategy. Tilray appointed Arne Wilkens as VP business expansion; José...
Bellicum Pharmaceuticals’ (NASDAQ:BLCM) registrational trial of rivo-cel achieved its primary endpoint of event-free survival when the drug was administered to patients receiving stem cell transplants.
Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR001, a gene therapy candidate for the treatment of Parkinson’s disease (PD).
Zenabis Global’s (TSX:ZENA) expansion in Stellarton, Nova Scotia, is good news for local residents, as the company is looking to fill several positions at that particular facility this summer.
The FDA approved Karyopharm Therapeutics (NASDAQ:KPTI) XPOVIO, in combination with dexamethasone, for the treatment of relapsed or refractory multiple myeloma (RRMM).
Ovid Therapeutics (NASDAQ: PTI) reported that, following a positive opinion from the European Medicines Agency, the European Commission granted OV101 orphan drug designation for the treatment of Angelman syndrome.
Zenabis Global (TSX:ZENA) entered into an agreement with High Park Holdings, a wholly-owned unit of Tilray (NASDAQ:TLRY), for High Park to advance $30- million (Canadian) to Zenabis in return for a supply of dried...